Detalles de la búsqueda
1.
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study.
Clinicoecon Outcomes Res;
16: 55-67, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348373
2.
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Mult Scler Relat Disord;
75: 104766, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37245350
3.
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
CNS Drugs;
36(7): 703-719, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35725892
4.
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
Neurology;
98(24): 1015-1020, 2022 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35470139
5.
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
CNS Drugs;
35(7): 743-767, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34228301
6.
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
Neurol Ther;
10(1): 169-182, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33225410
7.
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis.
Biomedicines;
7(1)2019 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30862055
8.
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.
Mult Scler J Exp Transl Clin;
5(1): 2055217318824618, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30729028
9.
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Mult Scler Relat Disord;
22: 27-34, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29524759
10.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Curr Med Res Opin;
30(2): 251-62, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24131282
11.
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Mult Scler;
11(4): 409-19, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16042223
Resultados
1 -
11
de 11
1
Próxima >
>>